$NOVO B (-7,73 %)
$NVO (-7,33 %)
Next entry 45
Puestos
49$NOVO B (-7,73 %)
$NVO (-7,33 %)
First entry
So I just realised that I've been investing for exactly 1 year and 1 week, so I thought this would be a good moment to reflect. I'm 36, the total portfolio size is 50k+ and the money isn't needed in short term. My portfolio summarised:
1. ETF core, 50% at minimum: $VDEV (+0,63 %) and $VFEM (+1,98 %) , recently added $EUE (+0,85 %) as I see more potential in the EU than in the US in the short-medium term. I like how a combination of these 3 ETFs allows for more adaptability than simply putting everything in a world ETF. Plus, the TER is a bit lower.
2. Individual stocks, max 10 positions, only including companies that I understand and have faith in that they will perform well in the next couple of years. The goal is to at least match $IWDA (+0,74 %) but preferably to make some additional gains. In summary:
Tech:
$NVDA (-1,35 %) : committed after the post-Deepseek dip, will just wait out all the short-term turbulence
$AMZN (-0,36 %) : doesn't need additional info.
$ASML (+0,02 %) : ditto
$VRT (+2,11 %) : see one of my previous posts on GQ. Bit too volatile for me now, but when the AI-hype picks up again, will perform well.
Health:
$NVO (-7,33 %) : I have a lot of faith in the GLP1-narrative, stock is very undervalued
$LLY (+14,61 %) : same at NVO, got pummeled hard recently but in longer term another good bet in the GLP1-race.
Divident:
$ALV (+0,81 %) : popular German insurance company. Divident-wise, I have more faith in insurance companies than banks. Banks also face more headwinds due to fintech.
$ASRNL (+0 %) : comparable to Allianz, solid, no-nonsense Dutch insurance company.
Bit more speculative:
$NU (+2,52 %) : I think fintech has a lot of potential and NU was valued quite cheaply compared to US- or EU-based counterparts. Could benefit from US recession if USD evaluates.
What are your thoughts? What would you add or lose? I'm thinking of adding $GOOG (-1,33 %) when the current downtrend subsides. Does make the portfolio more tech-heavy but all companies are internationally oriented (in case of US recession) and should outperform in the longer term.
Thanks in advance!
$NOVO B (-7,73 %) is currently on sale, so I bought another batch.
Today S&P reached an important support level and I started my buy strategy.
After that I bought back some $TROW (+1,15 %) shares, $NVO (-7,33 %) and $ENI (+1,55 %)
And I was thinking to add to my portfolio one of those, $GOOG (-1,33 %)
$META (+0,27 %) or $MSFT (-0,72 %) wich one would you choose?
$HIMS (+1,78 %)
$LLY (+14,61 %)
$NOVO B (-7,73 %)
$NVO (-7,33 %)
$NOVO B (-7,73 %) introduces NovoCare ® Pharmacy, which lowers the cost of all doses of FDA-approved Wegovy ® (semaglutide) to $499 per month and offers convenient home delivery for cash-paying patients.
While 90% of patients taking Wegovy ® have a co-pay of $0 to $25 per month, this offer was developed to support patients who are self-pay and do not have insurance coverage.
Podcast episode 77 "Buy High. Sell Low."
Subscribe to the podcast to get Novo & AMD back on track.
00:00:00 Novo Nordisk $NVO (-7,33 %)
$LLY (+14,61 %)
00:26:00 BYD $1211 (-1,57 %)
$TSLA (+0,65 %)
00:44:30 Nu Holdings $NU (+2,52 %)
01:07:00 AMD $AMD (-0,25 %)
$NVDA (-1,35 %)
$INTC (-0,72 %)
01:29:00 Election programs SPD & Greens
Spotify
https://open.spotify.com/episode/5PLVDJVROTrUKYtHMWj2Yz?si=5PvCiTPWRPaYPyQ3XcV-Iw
YouTube
https://youtu.be/Z2WkTM1NB6M?si=gXx_9DWNQpwkbDna
Apple Podcast
Have you had any home runs (from +15% price jump) this earnings season?
I haven't yet - hope for $ELF (+6,02 %) and $RIVN (+1,49 %) ...
... but I've also been hoping for $NVO (-7,33 %) , $ARM (-0,11 %)
$AMD (-0,25 %)
$LLY (+14,61 %) in vain so far ...
🔹 Q4 Revenue: DKK 85.68B (Est. DKK 80.29B) 🟢
🔹 Q4 Wegovy Sales: DKK 19.9B; More than doubled YoY
🔹 FY Revenue: DKK 290.40B (Est. DKK 285.57B) 🟢; UP +25% YoY
🔹 FY EBIT: DKK 128.34B (Est. DKK 125.96B) 🟢
Regional Breakdown:
🔹 North America Revenue: UP +30% YoY
🔹 International Operations Revenue: UP +17% YoY
Q4 Operating Metrics:
🔹 Operating Profit: DKK 36.7B (Est. DKK 33.6B) 🟢; UP +37% YoY
FY'25 Outlook:
🔹 Sales Growth: 16%-24% at CER
🔹 Operating Profit Growth: 19%-27% at CER
🔹 Sales and profit growth in DKK expected to be 3pp and 5pp higher than CER
Operational & Strategic Updates:
🔸 Completed acquisition of three Catalent manufacturing sites
🔸 R&D Progress: CagriSema and Semaglutide trials show superior weight loss efficacy
🔸 Dividend: Board to propose DKK 7.90/share final dividend (Total 2024 dividend: DKK 11.40/share, UP +21% YoY)
CEO Lars Fruergaard Jørgensen's Commentary:
🔸 "Strong 2024 performance with 26% sales growth, benefiting over 45M people globally. Focus remains on commercial execution, expanding R&D pipeline, and scaling production capacity in 2025."